Skip to main content

Table 1 Summary of patients characteristics at treatment start.

From: Neo-adjuvant chemo-radiation of rectal cancer with Volumetric Modulated Arc Therapy: summary of technical and dosimetric features and early clinical experience

   RA 3DC
Number of patients   25 20
Males   76% (19/25) 65% (13/20)
Females   24% (6/25) 35% (7/20)
Age [years] (median and range)   65.4 [37, 85] 63.5 [46, 79]
Hystology   Adenoca Adenoca
Stage T T2 0% (0/25) 15% (3/20)
  T3 84% (21/25) 75% (15/20)
  T4 16% (4/25) 10% (2/20)
Stage N N0 48% (12/25) 40% (8/20)
  N1 44% (11/25) 35% (7/20)
  N2 4% (1/25) 10% (2/20)
  Nx 4% (1/25) 15% (3/20)
Stage M M0 96% (24/25) 95% (19/20)
  M1 4% (1/25) 5% (1/20)
Grade G G1 4% (1/25) 10% 2/20)
  G2 84% (21/25) 90% (18/20)
  G3 12% (3/25) 0% (0/20)
Location Low 48% (12/25) 15% (3/20)
  Medium 16% (4/25) 45% (9/20)
  High 36% (9/25) 40% (8/20)
Chemotherapy Capecitabin 92% (23/25) 100% (20/20)
  No chemio 8% (2/25) 0% (0/20)
Surgery Pre-op 80% (20/25) 90% (18/20)
  Post-op 16% (4/25) 10% (2/20)
  Non-op 4% (1/25) 0% (0/20)
Radiation Dose Prescription 44 Gy/22 fractions 72% (18/25) 80% (16/20)
  45 Gy/25 fractions 20% (5/25) 20% (4/20)
  40 Gy/20 fractions 8% (2/25) 0% (0/20)
Radiation Boost 50.4 Gy 12% (3/25) 25% (5/20)
Dose Prescription 54.0 Gy 4% (1/25) 0% (0/20)
  1. Values are expressed in number of patients when not otherwise specified.